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Abstract
The leukocyte recruitment and transmigration across the endothelial barrier into the vessel wall are crucial steps in atherosclerosis. Leukocyte 
trafficking on the endothelium is elicited by induction of endothelial adhesion molecules, and its transmigration is mediated by degradation of basement
membrane proteins through enzymatic activity of matrix metalloproteinases (MMP). The current study investigated whether resveratrol, a polyphenol
present in grapes and red wine, was capable of inhibiting leukocyte adhesion to tumor necrosis factor (TNF)-α-activated endothelium. It was found 
that resveratrol inhibited the TNF-α-activated endothelial expression of vascular cell adhesion molecule-1 in a dose-dependent manner. In addition, 
resveratrol hampered THP-1 monocyte adhesion to activated endothelial cells. This study further examined whether resveratrol interfered with transendothelial
migration of leukocytes. The MMP-2 gelatinolytic activity of endothelial cells was enhanced by TNF-α, which was attenuated by an addition of
≥25 µM resveratrol. In addition, 25 µM resveratrol mitigated the MMP-9 activity of THP-1 cells, followed by a marked inhibition of transendothelial
migration. These results demonstrated that resveratrol suppressed monocyte adhesion and migration induced by TNF-α through modulating expression
of adhesion molecules and gelatinolytic activity of MMP. These findings suggest that dietary resveratrol may be therapeutic agent for inhibiting
leukocyte recruitment into the subendothelium during inflammatory atherosclerosis.
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Introduction7)
Circulating leukocytes adhere to endothelial cells and undergo 
transmigration through the vessel wall into the extracellular ma-
trix. Leukocyte extravasation requires the secretion of matrix- 
degrading enzymes, matrix metalloproteinases (MMP), which 
allow leukocytes to penetrate through the basement membrane. 
MMP can be divided into four categories based on substrate pre-
ference: collagenases, gelatinases, stromelysins and membrane- 
associated MMP. MMP-2 and MMP-9 preferentially degrade 
denatured gelatin and native collagen typeⅣ, which are one amo-
ng the main components of basal membranes. Transmigration 
and metastasis of macrophages and tumor cells require disruption 
of basement membrane, so that MMP-2 and MMP-9 have been 
suggested to play a critical role in such processes (Galis et al., 
1994; Nagaoka & Hirota, 2000; Saarialho-Kere et al., 1993).
The vascular endothelial cells are an important target of 
pro-inflammatory cytokine TNF-α (Pober & Cotran, 1990; Ross, 
1993), in which it modulates endothelial expression of many 
genes involved in cell adhesion, thrombosis and inflammatory 
responses leading to atherosclerosis (Krasinski et al., 2000). 
Adhesion molecules such as vascular cell adhesion molecule-1 
(VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) 
are shown to play an important role in the induction of 
inflammation (Berk et al., 2001; Nakashima et al., 1998). The 
VCAM-1 induction of is a common feature in inflammatory 
environments and occurs in the early development of athero-
sclerosis (Schonbeck et al., 2000). 
Several epidemiological studies have shown that red wine 
consumption is inversely related to cardiovascular disease 
(Aviram M & Fuhrman B, 2002; Belleville, 2002). Subsequently, 
multiple experiments have been conducted to demonstrate the 
pathophysiological activities of various components present in 
red wine. Resveratrol, a polyphenol subsisting in multiple plants 
including grapes and mulberries, is thought to be as a potential 
protective component (Bertelli et al., 1995; Hao & He, 2004). 
There is growing evidence that resveratrol can prevent or delay 
the onset of various cancers, heart diseases, ischemic and 
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chemically induced injuries, pathological inflammation and viral 
infections (Baur & Sinclair, 2006; Bradamante et al., 2004; 
Shankar et al., 2007). In a recent report (de Lange et al., 2007), 
red wine inhibited platelet functions through content of 
polyphenolic grape extract that stimulated the inhibitory receptor, 
platelet endothelial cell adhesion molecule-1 (PECAM-1), 
thereby attenuating platelet activation. In addition, resveratrol 
suppressed monocyte chemotactic protein-1 binding activity of 
THP-1 cells and its receptor CCR2 mRNA, indicating that these 
inhibitory effects of resveratrol on chemokine receptor binding 
and expression may contribute, in part, to its cardiovascular 
protective activity in vivo (Cullen et al., 2007).
On the basis of the literature evidence that resveratrol is a 
protective component preventing the onset of pathological infla-
mmation, the present study assessed the anti-inflammatory acti-
vity of resveratrol with respect to VCAM-1 expression in TNF-α
-exposed human umbilical vein endothelial cells (HUVEC). Fur-
thermore, the leukocyte extravasation was investigated by mea-
suring gelatinolytic activity of MMP and monocyte migration. 
MATERIALS AND METHODS
Materials
M199 medium chemicals, RPMI 1640 medium chemicals, 
Resveratrol and 3-(4, 5-dimetylthiazol-yl)-diphenyl tetrazolium 
bromide (MTT) were obtained from Sigma-Aldrich Co. (St. 
Louis, MO), as were all other reagents, unless specifically stated 
elsewhere. Collagenase was purchased from Worthington Bio-
chemicals (Lakewood, NJ). Fetal bovine serum (FBS), peni-
cillin-streptomycin, trypsin-EDTA, bovine brain extract, human 
epidermal growth factor and hydrocortisone were purchased from 
Cambrex Corporation (East Rutherford, NJ). Antibodies against 
human VCAM-1, human β-actin and human VCAM-1 were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Horseradish peroxidase-conjugated goat anti-rabbit IgG was 
provided as a secondary antibody by the Jackson Immu-
noResearch Laboratory (West Grove, PA). Human monocytic 
leukemic cell line THP-1 was obtained from American Type 
Culture Collection (Rockville, MD). TNF-α was obtained from 
Roche Molecular Biochemicals (Mannheim, Germany).
Preparation and culture of HUVEC 
HUVEC were isolated from umbilical cords using collagenase 
as described elsewhere (Choi et al., 2005). Cultures were 
maintained at 37℃ humidified atmospheres of 5% CO2 in air. 
Cells were cultured in 25 mM HEPES-buffered M199 containing 
10% FBS, 2 mM glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin supplemented with 0.75 mg/mL human epidermal 
growth factor and 0.075 mg/mL hydrocortisone. Cells were 
passaged at confluence and used within 10 passages. Endothelial 
cells were confirmed by their cobblestone morphology and 
uptake of fluorescent 1.1’-dioctadecyl-3,3,3’,3’-tetramethylindo-
carbocyanine perchlorate-labeled acetylated LDL.
HUVEC were plated at 90-95% confluence in all experiments. 
In experiments for resveratrol dose responses to TNF-α-induced 
VCAM-1 expression and MMP-2 activity, cells were incubated 
with 1-50 µM resveratrol overnight and subsequently exposed 
to 10 ng/mL TNF-α for 6 h. It has been shown by using 
high-performance liquid chromatography that concentrations of 
trans-resveratrol in human plasma ranged 15.0-4,000 ng/mL with 
intra-assay variability of 1.9-3.7% and inter-assay variability of 
2.5-4.0% (Zhu et al., 1999).
Culture of THP-1 cells and in vitro cell adhesion assay
HUVEC were grown in 25 mM HEPES-buffered at a density 
of 1.0 × 10
5 cells on 4-well glass chamber slides. Human mono-
cytic THP-1 cells were labeled with 5 µM calcein-AM (Mole-
cular Probes Inc., Eugene, OR) in RPMI 1640 medium containing 
10% FBS. Cells were pre-treated with 10-50 µM resveratrol 
overnight prior to the 6 h exposure to 10ng/mL TNF-α. In the 
co-culture models, the labeled THP-1 cells were seeded at a 
density of 5.0 × 10
5 cells onto near-confluent monolayer of HU-
VEC treated with the resveratrol and/or TNF-α and were 
incubated for 2 h. After the co-cultured cells were thoroughly 
washed, photograph images were obtained at 485 nm excitation 
and 538 nm emission using a SPOT II digital camera-attached 
fluorescence microscope with Spot II data acquisition software 
(Diagnostic Instrument, Livingston, Scotland).
Western blot analysis 
For the VCAM-1 induction by TNF-α, whole cell extracts 
were prepared from resveratrol-treated and TNF-α-exposed 
HUVEC in 1 M Tris-HCl (pH 6.8) lysis buffer containing 10% 
SDS, 1% β-glycerophosphate, 0.1 M Na3VO4, 0.5 M NaF and 
protease inhibitor cocktail. Cell lysates with equal amounts of 
total protein were fractionated by electrophoresis on 8% SDS- 
PAGE gels and transferred onto a nitrocellulose membrane. 
Nonspecific binding was blocked by soaking the membrane in 
TBS-T buffer [0.5 M Tris-HCl (pH 7.5), 1.5 M NaCl, and 0.1% 
Tween 20] containing 5% nonfat dry milk for 3 h. The membrane 
was incubated for 3 h with a primary polyclonal rabbit anti- 
human VCAM-1 antibody after three washes with TBS-T buffer, 
the membrane was then incubated for 1 h with horseradish 
peroxidase-conjugated goat anti-rabbit IgG. The protein level of 
VCAM-1 was determined by using Supersignal West Pico chemi-
luminescence detection reagents (Pierce Biotech. Inc., Rockford, 
IL) and Konica X-ray film (Konica Co., Tokyo, Japan). Incu-
bation with monoclonal mouse β-actin antibody was also perfor-
med for the comparative control.
Gelatin zymography
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Fig. 1. Inhibitory dose response of THP-1 monocytes adhesion to resveratrol 
in TNF-α-activated HUVEC. HUVEC  were  pre-treated  at  10-50  µM  resveratrol 
overnight and then activated with 10 ng/mL TNF-α for 6 h. Endothelial cells were 
co-cultured with calcein AM-labeled THP-1 monocytes for 2 h. Microphotographs 
(3  independent  experiments)  were  obtained  using  a  fluorescence  microscopy. 
Magnification  X200.  The  bar  graphs  (bottom  panel)  represent  quantitative  results 
obtained by using a Fluoroscan ELISA plate reader at λ=485 nm excitation and 
λ=538 nm emission. *p＜0.05, relative to TNF-α-untreated control incubation. 
+p
＜0.05,  relative  to  TNF-α-alone  incubation. 
Fig. 2. Resveratrol inhibition of VCAM-1 induction in TNF-α-stimulated HUVEC.
After culturing HUVEC with 10-50 µM resveratrol and 10 ng/mL TNF-α, cell extr-
acts were subjected to 8% SDS-PAGE, followed by Western blot analysis with a 
VCAM -1 prim ary antib ody. β -Actin protein was used  as an internal control. The 
bar graphs (bottom panel) represent densitometric results (3 independent experim-
ents). *p＜0.05, relative to TNF-α-untreated control incubation. 
+p＜0.05, relative 
to TNF-α-alone incubation.
 + + p＜0.05, relative to incubation with 25 µM resveratrol.
ratio of 5 to1 with sample buffer and electrophoresed in 10% 
SDS-PAGE containing 1 mg/mL gelatin. Gels were renaturated 
by exchanging SDS for 2.5% Triton X-100, followed by 20 h 
incubation at 37℃ in the activation buffer (50 mM Tris, pH 7.5, 
10 mM CaCl2, 0.2 M NaCl and 0.05% Brij). Gels were subse-
quently stained with Coomassie blue staining solution (0.1% 
Coomassie R250; 45% MeOH; 2% acetic acid) for 1 h, followed 
by being destained with 30% MeOH and 10% acetic acid. 
THP-1 cell migration 
The experimental models for the monocyte migration emp-
loyed 24-transwell inserts with pore sizes of 3 µm (Corning 
Incorp., Corning, NY). The lower surface of the insert filter was 
coated with 10 µL of 1 mg/mL gelatin solution and dried for 
1 h. THP-1 cell suspensions of 10
6 cells/mL in serum-free RPMI 
1640 were loaded in the upper compartment of the transwell 
chamber. The cells were treated with 25 µM resveratrol and 
exposed to 10 ng/mL TNF-α for 48 h. Transmigration was 
stopped by removing the transwell insert. The number of cells 
that had migrated to the lower compartment across the lower 
gelatin surface of the filter was counted microscopically. In 
addition, photography was obtained using a Motic AE30/31 
inverted microscope (Motic Co., Xiamen, China). 
Data analysis
The results are presented as mean ± SEM for each treatment 
group in each experiment. Statistical analyses were conducted 
using Statistical Analysis Systems statistical software package 
(SAS Institute Inc., Cary, NC). Significance was determined by 
one-way ANOVA followed by Duncan multiple range test for 
multiple comparisons. P values <0.05 were considered statisti-
cally significant.
Result
Inhibition of TNF-α-induced monocyte adhesion by resveratrol
The in vitro data for the THP-1 cell adhesion to HUVEC was 
shown in Fig. 1. A small number of monocytes were adhered 
to quiescent HUVEC free of 10 ng/mL TNF-α. There was heavy 
staining in TNF-α-alone-exposed HUVEC, indicative of a 
substantial increase in the THP-1 cell adherence to the activated 
HUVEC. However, adding resveratrol at non-toxic doses of 
10-50 µM to TNF-α-exposed cells markedly attenuated the 
monocyte adherence in a dose-dependent manner (Fig. 1). It 
should be noted that ≥10 µM resveratrol was effective in 
inhibiting leukocyte adhesion to cytokine-activated endothelium.
Mitigation of TNF-α-induced expression of VCAM-1 by 
resveratrol
Western blot analysis was performed to address that resveratrol 
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Fig. 3. Gelatinolytic activity of MMP-2 (A) and MMP-9 (B) in TNF-α-exposed 
HUVEC and THP-1 cells. HUVEC (for MMP-2) and THP-1 cells (for MMP-9) were 
with  25  µM  resveratrol  overnight  prior  to  an  addition  of  10  ng/mL  TNF-α  and 
continuously  incubated  for  24  h.  The  collected  culture  media  were  subjected  to 
electrophoresis on 10% SDS-PAGE co-polymerized by 0.1% gelatin  as th e su b-
strate. Gelatinolytic activities were detected as unstained bands against the back-
ground of Coomassie blue-stained gelatin and gel photographs (3 separate expe-
riments)  were  obtained.
Fig. 4. Resveratrol inhibition of TNF-α-induced THP-1 monocyte transmigration.
THP-1 cells were incubated by serum free-RPMI-1640 on the transwell chamber 
coated with 0.1% gelatin on its lower surface. Subsequently, cells were incubated 
for 48 h in the presence of 25 µM resveratrol and 10 ng/mL TNF-α. THP-1 cells 
migrated  to  the  lower  compartment  of  transwell  chamber  were  microscopically 
photographed. The THP-1 cell migration ability was defined by the number of THP-1 
cells  migrated.  *p＜0.05,  relative  to  TNF-α-untreated  control  incubation.
of VCAM-1 protein was greatly elevated in TNF-α-stimulated 
HUVEC over the quiescent cells (Fig. 2). When resveratrol was 
supplemented in the range between 10 and 50 µM, the enhanced 
expression of VCAM-1 dose-dependently declined. This data 
showed that ≥25 µM resveratrol diminished the TNF-α-stimu-
lated expression of VCAM-1. These results imply that other 
adhesion molecules such as ICAM-1 and PECAM-1 may be 
involved in blocking the leukocyte trafficking. 
Gelatinolytic activity of MMP-2 and MMP-9
When HUVEC were treated with 10 ng/mL TNF-α under 
serum-free conditions, the gelatin zymography revealed that the 
gelatinolytic activity of MMP-2 active form secreted in culture 
media within 24 h was substantially increased (Fig. 3A). In 
contrast, the treatment of TNF-α-exposed HUVEC with resver-
atrol mitigated the increased gelatinolytic activity of MMP-2 
active form (69 and 68 kDa) only at its concentrations of ≥25 
µM (Fig. 3A). It should be noted that the pro-form of MMP-2 
(72 kDa) secretion was not influenced in presence of TNF-α 
and/or resveratrol. In addition, the enzyme activity of pro-form 
MMP-9 (92 kDa) secreted from TNF-α-added THP-1 cells was 
elevated, whereas 25 µM resveratrol markedly suppressed the 
MMP-9 activity (Fig. 3B). The active form of MMP-9 (82 kDa) 
was not apparent in TNF-α-exposed HUVEC. 
Blockade of TNF-α-induced THP-1 migration by resveratrol.
Fig. 4 showed inhibitory effects of resveratrol on THP-1 
transmigration into the vascular matrix tissue. The THP-1 cell 
migration across the gelatin layer mimicking basement mem-
branes was markedly augmented within 48 h after an addition 
of TNF-α. On the contrary, the elevated monocyte transmigra-
tion was abolished by 25 µM resveratrol, indicating that res-
veratrol blunted cytokine-stimulated monocyte extravasation 
effectively through suppressing secretion of gelatinolytic MMP 
and subsequent degradation of vascular matrix. 
Discussion
This study attempted to test the hypothesis that resveratrol, 
a polyphenol found in red wine and peanuts, inhibits monon-
uclear leukocyte recruitment on the TNF-α-induced vascular 
endothelium. Four major findings were observed from this study. 
1) Resveratrol at the non-toxic dose of ≥10 µM, nearly abolished 
THP-1 adhesion onto TNF-α-exposed cells. 2) Adding resvera-
trol in the dose range between 10 and 50 µM dose-dependently 
attenuated expression of VCAM-1 up-regulated by TNF-α. 3) 
When resveratrol at the doses of ≥25 µM was supplemented 
to TNF-α-exposed endothelial cells, the elevated gelatinolytic 
activity of MMP-2 was mitigated. In addition, the enhanced 
activity of MMP-9 was reduced in 25 µM resveratrol-treated 
THP-1 cells. 4) Resveratrol at the dose of 25 µM suppressed 
the transmigration of THP-1 monocytes exposed to TNF-α. 
These overall observations demonstrate that resveratrol has the 
potential capability to prevent the early events in atherosclerosis. 
The ability to block the TNF-α-induced monocyte trafficking 
and extravasation argues for the major target of action of Dong Shoo Kim et al. 289
resveratrol. 
Numerous studies have focused on beneficial effects of 
polyphenols on cardiovascular functions including improvement 
of endothelial function, inhibition of angiogenesis and cell 
migration and proliferation in blood vessels (Choi et al., 2005; 
Katiyar, 2006; Middleton et al., 2000; Nijveldt et al., 2001). 
There is compelling evidence that the distinct structures of 
polyphenols appear to be partially responsible for their protective 
functions (Fukuhara et al., 2006; Hu et al., 2006; Teixeira et 
al., 2005). The mechanisms triggered by polyphenols with 
specific structures contribute to the vasoprotective, anti-angio-
genic, anti-atherogenic, vasorelaxant and anti-hypertensive effe-
cts found in animals and in patients (Stoclet et al., 2004). In 
addition, the current evidence suggests that there is a plausible 
target for inhibiting atherosclerosis by grapes and/or its poly-
phenolic constituents through modulating novel pathways invo-
lved in the leukocyte extravasation. 
Moderate consumption of red wine has been associated with 
beneficial effects on cardiovascular diseases, which is the 
phenomenon named as the French paradox (Belleville, 2002; 
Bertelli  et al., 1995; Hao & He, 2004). Resveratrol has been 
regarded as the potential protective polyphenol present in red 
wine. In the present study resveratrol blunted monocyte adhesion 
onto the activated endothelial cells and its transmigration across 
a gelatin matrix barrier, indicating that resveratrol is capable to 
block the early process of atherosclerosis. It was reported that 
resveratrol might improve obesity-induced atherosclerosis by 
modulating the TNF-α-induced secretion changes of adipokine 
and adiponectin (Ahn et al., 2007). Additionally, resveratrol 
suppressed monocyte chemotactic protein-1 receptor CCR2 
binding and expression of THP-1 cells responsible for athero-
sclerosis (Cullen et al., 2007). However, this study did not 
elucidate possible mechanisms by which resveratrol conferred the 
beneficial effects in endothelial responses to cytokines during 
inflammation. It was suggested that resveratrol be an antioxidant 
protecting endothelial cells from oxidized LDL-induced oxidative 
stress via direct ROS scavenging and inhibition of NADPH 
oxidase activity (Chow et al., 2007). In addition, this polyphenol 
inhibited IL-6-induced ICAM-1 gene expression, in part, by 
interfering with Rac-mediated pathways via the attenuation of 
STAT3 phosphorylation (Wung et al., 2005). 
MMP-2 and MMP-9 preferentially degrade denatured gelatin 
and native collagen typeⅣ, which are the main components of 
basal membranes. Accordingly, transmigration of macrophages 
requires disruption of basement membrane, and thus MMP-2 and 
MMP-9 have been implied to play a critical role in such processes 
(Galis et al., 1994; Nagaoka & Hirota, 2000; Saarialho-Kere et 
al., 1993). The present study showed that resveratrol interfered 
with monocyte transmigration concomitantly with dampening 
MMP secretion of endothelial cells and monocyes. A dose-related 
decrease of MMP-2 production after resveratrol treatment of 
human cultured glioblastoma cells revealed that resveratrol may 
influence the ECM remodeling occurring with tumor invasion 
(Gagliano  et al., 2005). It was also shown that resveratrol 
inhibited phorbol myristate acetate-induced MMP-9 expression 
by inhibiting signal transduction of c-Jun N-terminal kinase and 
protein kinase Cδ (Woo  et al., 2004). Considerable interest is 
increasing with regard to the use of dietary botanical supplements 
for chemopreventive and neuro- and cardiovascular-protective 
effects. Indeed, dietary botanicals such as green tea polyphenols 
and grape seed proanthocyanidins have been considered as MMP 
inhibitors and as cancer chemo-therapeutic agents (Katiyar, 
2006). 
In summary, the current study has demonstrated that resveratrol 
is capable of preventing early processes of atherosclerosis 
involving inducible VCAM-1 expression and MMP secretion. 
Resveratrol blocked monocyte adhesion onto the TNF-α
-activated endothelium most likely via the down-regulation of 
VCAM-1 expression. In addition, this compound inhibited mat-
rix-degrading MMP secretion from cytokine-activated endothelial 
cells and monocytes. This observation might have clinical 
implications for therapeutic strategies preventing and attenuating 
inflammatory diseases. Although definite mechanisms underlying 
the protection of resveratrol against early atherogenic process are 
not fully defined in this study, the VCAM-1 expression and MMP 
secretion may be a pivotal target of anti-atherogenic actions of 
resveratrol.
Literature cited
Ahn J, Lee H, Kim S & Ha T (2007). Resveratrol inhibits TNF-α
-induced changes of adipokines in 3T3-L1 adipocytes. Biochem 
Biophys Res Commun 364:972-977.
Aviram M & Fuhrman B (2002). Wine flavonoids protect against 
LDLoxidation and atherosclerosis. Ann NY Acad Sci 957:146-161.
Baur JA & Sinclair DA (2006). Therapeutic potential of resveratrol: 
the in vivo evidence. Nat Rev Drug Discov 5:493-506.
Belleville J (2002). The French paradox: possible involvement of 
ethanol in the protective effect against cardiovascular diseases. 
Nutrition 18:173-177. 
Berk BC, Abe JI, Min W, Surapisitchat H & Yan C (2001). 
Endothelial atheroprotective and anti-inflammatory mechanisms. 
Ann N Y Acad Dci 947:93-111.
Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, 
Fregoni M & Bertelli A (1995). Antiplatelet activity of synthetic 
and natural resveratrol in red wine. Int J Tissue React 17:1-3.
Bradamante S, Barenghi L & Villa A (2004). Cardiovascular prote-
ctive effects of resveratrol. Cardiovasc Drug Rev 22:169-188.
Choi YJ, Jeong YJ, Lee YJ, Kwon HM & Kang YH (2005). (-) 
Epigallocatechin gallate and quercetin enhance survival signaling 
in response to oxidant-induced human endothelial apoptosis. J Nutr 
135:707-713.
Chow SE, Hshu YC, Wang JS & Chen JK (2007). Resveratrol 
attenuates oxLDL-stimulated NADPH oxidase activity and protects 
endothelial cells from oxidative functional damages. J Appl 
Physiol  102:1520-1527.
Cullen JP, Morrow D, Jin Y, von Offenberg Sweeney N, Sitzmann 
JV, Cahill PA & Redmond EM (2007). Resveratrol inhibits 290 Resveratrol inhibiting monocyte adhesion and migration
expression and binding activity of the monocyte chemotactic 
protein-1 receptor, CCR2, on THP-1 monocytes. Atherosclerosis 
195:e125-e133. 
de Lange DW, Verhoef S, Gorter G, Kraaijenhagen RJ, van de Wiel 
A & Akkerman JW. (2007) Polyphenolic grape extract inhibits 
platelet activation through PECAM-1: an explanation for the 
French paradox. Alcohol Clin Exp Res 31:1308-1314. 
Fukuhara K, Nagakawa M, Nakanishi I, Ohkubo K, Imai K, Urano 
S, Fukuzumi S, Ozawa T, Ikota N, Mochizuki M, Miyata N & 
Okuda H (2006). Structural basis for DNA-cleaving activity of 
resveratrol in the presence of Cu
2+.  Bioorg Med Chem 14: 
1437-1443. 
Gagliano N, Moscheni C, Torri C, Magnani I, Bertelli AA & Gioia 
M (2005). Effect of resveratrol on matrix metalloproteinase-2 
(MMP-2) and Secreted Protein Acidic and Rich in Cysteine 
(SPARC) on human cultured glioblastoma cells. Biomed Phar-
macother  59:359-364.
Galis ZS, Sukhova GK, Lark MW & Libby P (1994). Increased 
expression of matrix metalloproteinases and matrix degrading 
activity in vulnerable regions of human atherosclerotic plaques. J 
Clin Invest 94:2493-2503.
Hao HD & He LR (2004). Mechanisms of cardiovascular protection 
by resveratrol. J Med Food 7:290-298.
Hu J, Huang Y, Xiong M, Luo S, Chen Y & Li Y (2006). The effects 
of natural flavonoids on lipoxygenase-mediated oxidation of 
compounds with a benzene ring structure-a new possible mech-
anism of flavonoid anti-chemical carcinogenesis and other toxi-
cities.  Int J Toxicol 25:295-301.
Katiyar SK (2006). Matrix metalloproteinases in cancer metastasis: 
molecular targets for prostate cancer prevention by green tea 
polyphenols and grape seed proanthocyanidins. Endocr Metab 
Immune Disord Drug Targets 6:17-24. 
Krasinski K, Spyridopoulos I, Kearney M & Losordo DW (2000). 
In vivo blockade of tumor necrosis factor-alpha accelerates func-
tional endothelial recovery after balloon angioplasty. Circulation 
104:1754-1756.
Middleton E. Jr, Kandaswami C & Theoharides TC (2000). The 
effects of plant flavonoids on mammalian cells: implications for 
inflammation heart disease and cancer. Pharmacol Rev 52:673- 
751.
Nagaoka I & Hirota S (2000). Increased expression of matrix 
metalloproteinase-9 in neutrophils in glycogen-induced peritoneal 
inflammation of guinea pigs. Inflamm Res 49:55-62.
Nakashima Y, Raines EW, Plump AS, Breslow JL & Ross R (1998). 
Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone 
sites on the endothelium in the Apo-E-deficient mouse. Arteri-
oscler Thromb Vasc Biol 18:842-851.
Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren 
K & van Leeuwen PA (2001). Flavonoids: a review of probable 
mechanisms of action and potential applications. Am J Clin Nutr 
74:418-425.
Pober JS & Cotran RS (1990). The role of endothelial cells in 
inflammation.  Transplantation  50:537-533.
Ross R (1993). The pathogenesis of atherosclerosis: a perspective for 
the 1990s. Nature  362:801-809.
Saarialho-Kere UK, Welgus HG & Parks WC (1993). Distinct 
mechanisms regulate interstitial collagenase and 92-kDa gelatinase 
expression in human monocytic-like cells exposed to bacterial 
endotoxin.  J Biol Chem 268:7354-7361.
Schonbeck U, Mach F & Libby P (2000). CD154 (CD40 ligand). Int 
J Biochem Cell Biol 32:687-693.
Shankar S, Singh G & Srivastava RK (2007). Chemoprevention by 
resveratrol: molecular mechanisms and therapeutic potential. Front 
Biosci 12:4839-4854.
Stoclet JC, Chataigneau T, Ndiaye M, Oak MH, El Bedoui J, 
Chataigneau M & Schini-Kerth VB (2004). Vascular protection by 
dietary polyphenols. Eur J Pharmacol 500:299-313. 
Teixeira S, Siquet C, Alves C, Boal I, Marques MP, Borges F, Lima 
JL & Reis S (2005). Structure-property studies on the antioxidant 
activity of flavonoids present in diet. Free Radic Biol Med 
39:1099-108
Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, Lee YH, 
Park JW & Kwon TK (2004). Resveratrol inhibits phorbol 
myristate acetate-induced matrix metalloproteinase-9 expression by 
inhibiting JNK and PKC delta signal transduction. Oncogene 
23:1845-1853.
Wung BS, Hsu MC, Wu CC & Hsieh CW (2005). Resveratrol 
suppresses IL-6-induced ICAM-1 gene expression in endothelial 
cells: effects on the inhibition of STAT3 phosphorylation. Life Sci 
78:389-397. 
Zhu Z, Klironomos G, Vachereau A, Neirinck L & Goodman DW 
(1999). Determination of trans-resveratrol in human plasma by 
high-performance liquid chromatography. J Chromatogr B 724: 
389-392.